Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

被引：0
|
作者：
Christian Zurth
Mikko Koskinen
Robert Fricke
Olaf Prien
Timo Korjamo
Kristina Graudenz
Karsten Denner
Michaela Bairlein
Clemens-Jeremias von Bühler
Gary Wilkinson
Hille Gieschen
机构：
[1] Bayer AG,
[2] Orion Corporation,undefined
[3] Orion Pharma,undefined
[4] Bayer AG,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2019年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：747 / 759
页数：12
相关论文
共 50 条
  • [41] Screening of drug candidates for their drug-drug interaction potential
    Rodrigues, AD
    Lin, JH
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) : 396 - 401
  • [42] STUDIES OF DRUG INTERACTION
    BELLVILLE, JW
    ANESTHESIOLOGY, 1970, 33 (03) : 373 - +
  • [43] In vitro drug interaction studies of atorvastatin with ciprofloxacin, gatifloxacin, and ofloxacin
    Arayne, M. Saeed
    Sultana, Najma
    Rizvi, Syeda Bushra Shakeb
    Haroon, Urooj
    MEDICINAL CHEMISTRY RESEARCH, 2010, 19 (08) : 717 - 731
  • [44] In vitro drug interaction of levocetirizine and diclofenac: Theoretical and spectroscopic studies
    Dena, Ahmed S. Abo
    Gaber, Sara A. Abdel
    SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2017, 181 : 239 - 248
  • [45] In vitro metabolic interaction studies: Experience of the Food and Drug Administration
    Yuan, R
    Parmelee, T
    Balian, JD
    Uppoor, RS
    Ajayi, F
    Burnett, A
    Lesko, LJ
    Marroum, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (01) : 9 - 15
  • [46] In vitro drug interaction studies of atorvastatin with ciprofloxacin, gatifloxacin, and ofloxacin
    M. Saeed Arayne
    Najma Sultana
    Syeda Bushra Shakeb Rizvi
    Urooj Haroon
    Medicinal Chemistry Research, 2010, 19 : 717 - 731
  • [47] Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models
    Ryu, Hyo-jeong
    Moon, Hyun-ki
    Lee, Junho
    Yang, Gi-hyeok
    Yang, Sung-yoon
    Yun, Hwi-yeol
    Chae, Jung-woo
    Kang, Won-ho
    PHARMACEUTICALS, 2021, 14 (07)
  • [48] Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
    Li, Xiaoli
    Liu, Yuyan
    Zhu, Minhui
    He, Cuixia
    Xu, Yuanyuan
    Ding, Jiaxiang
    Wang, Ying
    Shan, Rongfang
    Liu, Bingyan
    Ding, Yuzhou
    Xie, Jing
    Zhou, Huan
    Wang, Zhiqiang
    Liu, Yuanyuan
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 453 - 462
  • [49] In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates
    Rautio, J
    Humphreys, JE
    Webster, LO
    Balakrishnan, A
    Keogh, JP
    Kunta, JR
    Serabjit-Singh, CJ
    Polli, JW
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) : 786 - 792
  • [50] Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials
    Xiaoli Li
    Yuyan Liu
    Minhui Zhu
    Cuixia He
    Yuanyuan Xu
    Jiaxiang Ding
    Ying Wang
    Rongfang Shan
    Bingyan Liu
    Yuzhou Ding
    Jing Xie
    Huan Zhou
    Zhiqiang Wang
    Yuanyuan Liu
    Investigational New Drugs, 2023, 41 : 453 - 462
12345